Base de dados : MEDLINE
Pesquisa : D06.472.699.584.625 [Categoria DeCS]
Referências encontradas : 12205 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1221 ir para página                         

  1 / 12205 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470756
[Au] Autor:Roubinian NH; Looney MR; Keating S; Kor DJ; Lowell CA; Gajic O; Hubmayr R; Gropper M; Koenigsberg M; Wilson GA; A Matthay M; Toy P; Murphy EL; TRALI Study Group
[Ad] Endereço:Blood Systems Research Institute.
[Ti] Título:Differentiating pulmonary transfusion reactions using recipient and transfusion factors.
[So] Source:Transfusion;57(7):1684-1690, 2017 07.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: It is increasingly recognized that recipient risk factors play a prominent role in possible transfusion-related acute lung injury (pTRALI) and transfusion-associated circulatory overload (TACO). We hypothesized that both transfusion and recipient factors including natriuretic peptides could be used to distinguish TRALI from TACO and pTRALI. STUDY DESIGN AND METHODS: We performed a post hoc analysis of a case-control study of pulmonary transfusion reactions conducted at the University of California at San Francisco and Mayo Clinic, Rochester. We evaluated clinical data and brain natriuretic peptides (BNP) levels drawn after transfusion in patients with TRALI (n = 21), pTRALI (n = 26), TACO (n = 22), and controls (n = 24). Logistic regression and receiver operating characteristics curve analyses were used to determine the accuracy of clinical and biomarker predictors in differentiating TRALI from TACO and pTRALI. RESULTS: We found that pTRALI and TACO were associated with older age, higher fluid balance, and elevated BNP levels relative to those of controls and TRALI. The following variables were useful in distinguishing cases of pTRALI and TACO from TRALI: age more than 70 years, BNP levels more than 1000 pg/mL, 24-hour fluid balance of more than 3 L, and a lower number of transfused blood components. Using the above variables, our logistic model had a 91% negative predictive value in the differential diagnosis of TRALI. CONCLUSIONS: Models incorporating readily available clinical and biomarker data can be used to differentiate transfusion-related respiratory complications. Additional studies examining recipient risk factors and the likelihood of TRALI may be useful in decision making regarding donor white blood cell antibody testing.
[Mh] Termos MeSH primário: Lesão Pulmonar Aguda/etiologia
Reação Transfusional/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
Peptídeo Natriurético Encefálico/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
114471-18-0 (Natriuretic Peptide, Brain)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14118


  2 / 12205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29304158
[Au] Autor:Kitagawa T; Oda N; Mizukawa M; Hidaka T; Naka M; Nakayama S; Kihara Y
[Ad] Endereço:Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan.
[Ti] Título:Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels.
[So] Source:PLoS One;13(1):e0190979, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients with heart failure (HF) are reportedly at high risk for 'all-cause' re-hospitalization. A biomarker for HF, N-terminal pro-brain natriuretic peptide (NT-proBNP), enables to simply detect patients with possible HF (pHF). We examined the hospitalization and medical cost of Japanese patients detected by an elevated serum NT-proBNP, and also evaluated the effects of institutional team approaches for HF on their all-cause hospitalizations. METHODS: We retrospectively extracted all adult patients with serum NT-proBNP ≥400 pg/ml measured between January and March 2012 in Hiroshima University Hospital as pHF-positive patients. We studied their all-cause hospitalization records during the past 3-year period. We also extracted all pHF-negative patients with NT-proBNP <400 pg/ml and studied as well. In the pHF-positive patients followed for 3 years after starting interprofessional team approaches to prevent the onset and exacerbation of HF in the hospital, we compared the hospitalization and medical cost between the 3-year periods before and after the start of the team approaches. RESULTS: We enrolled 432 pHF-positive and 485 pHF-negative patients with one or more hospitalization records. Compared to the pHF-negative patients, the pHF-positive patients had longer total hospitalization days (median [interquartile range], 30 [13-58] versus. 18 [8-39], p <0.0001) and higher total medical cost for hospitalizations (2.42 [1.07-5.08] versus. 1.80 [0.79-3.65] million yen, p <0.0001). A subset of 303 pHF-positive patients was followed for 3 years after starting the team approaches, and we found that both total hospitalization days (30 [13-57] to 8 [0-31]) and medical cost for hospitalizations (2.59 [1.37-5.05] to 0.76 [0-2.38] million yen) showed marked reduction in them. CONCLUSIONS: Patients with an elevated serum NT-proBNP have longer hospitalizations and higher costs for all-cause hospitalizations than those without. Institutional team approaches for HF may reduce them.
[Mh] Termos MeSH primário: Insuficiência Cardíaca/sangue
Insuficiência Cardíaca/economia
Custos Hospitalares
Hospitalização
Peptídeo Natriurético Encefálico/sangue
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Tempo de Internação
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
114471-18-0 (Natriuretic Peptide, Brain)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190979


  3 / 12205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173360
[Au] Autor:Han L; Luo J; Bai S; Jia Y; Chen X; Zhao Y; Chen L; Zhu X; Li Y; Jiang Y; Li X; Yang M; Li D; Teng X; Qi Y
[Ad] Endereço:Department of Cardiology, Fu Xing Hospital, Capital Medical University, Beijing, China.
[Ti] Título:Combined Assessment of Relaxin and B-Type Natriuretic Peptide Improves Diagnostic Value in Patients With Congestive Heart Failure.
[So] Source:Am J Med Sci;354(5):480-485, 2017 11.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To improve the poor prognosis of congestive heart failure (CHF), early and accurate diagnosis is necessary. Relaxin is an endogenous cardiovascular peptide, and its plasma level is usually increased in patients with CHF. In this pilot study, we aimed to determine the diagnostic value of relaxin and B-type natriuretic peptide (BNP) in patients with and without CHF. MATERIALS AND METHODS: The plasma level of relaxin was measured by enzyme-linked immunosorbent assay and plasma level of BNP by fluorescence immunoassay. The area under the receiver operating characteristic curve was used to assess the diagnostic value of relaxin and BNP. RESULTS: We included 81 patients with decompenstated CHF and 36 controls. Plasma levels of relaxin and BNP were both higher in CHF patients than in controls. The correlation between plasma levels of relaxin and BNP and between relaxin or BNP and cardiac function was nonlinear. Relaxin had medium diagnostic value, and BNP had higher value for cardiac function and CHF. At a cutoff of 39.76pg/mL relaxin, sensitivity was 82.7%, specificity 55.6%, sum of the highest positive predictive value 80.5% and negative predictive value 58.8%. Although the diagnostic value was not better for relaxin than BNP, their combined assessment improved the sensitivity and specificity of diagnosis for CHF as compared with BNP alone. CONCLUSIONS: Combined assessment of relaxin and BNP may improve the diagnosis of decompensated CHF, which may have potential application in the clinic.
[Mh] Termos MeSH primário: Ensaio de Imunoadsorção Enzimática
Fluorimunoensaio
Insuficiência Cardíaca/diagnóstico
Peptídeo Natriurético Encefálico/sangue
Relaxina/sangue
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
China
Feminino
Insuficiência Cardíaca/sangue
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Valor Preditivo dos Testes
Curva ROC
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
114471-18-0 (Natriuretic Peptide, Brain); 9002-69-1 (Relaxin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  4 / 12205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28456775
[Au] Autor:Bartus K; Podolec J; Lee RJ; Kapelak B; Sadowski J; Bartus M; Oles K; Ceranowicz P; Trabka R; Litwinowicz R
[Ad] Endereço:Department of Cardiovascular Surgery and Transplantology, Jagiellonian University, Collegium Medicum, John Paul II Hospital, Cracow, Poland.
[Ti] Título:Atrial natriuretic peptide and brain natriuretic peptide changes after epicardial percutaneous left atrial appendage suture ligation using LARIAT device.
[So] Source:J Physiol Pharmacol;68(1):117-123, 2017 Feb.
[Is] ISSN:1899-1505
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Percutaneous left atrial appendage closure is an alternative treatment for stroke and systemic thromboembolism risk reduction in non-valvular atrial fibrillation (AF). However, the neurohormonal impact of epicardial exclusion of the left atrial appendage (LAA) with the LARIAT procedure is unknown. Evaluation of changes in atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) levels in AF patients underwent percutaneous LAA suture ligation. Sixty six patients underwent successfully percutaneous LAA suture ligation using LARIAT device. The level of ANP and BNP was measured before and 3 months after procedure. Mean ANP level before procedure was 249 ± 77 pg/mL (range from 95 pg/mL to 503 pg/mL) and mean BNP level was 481 ± 517 pg/mL (range from 34 pg/mL to 2508 pg/mL). Three months after procedure mean ANP level was 249 ± 79 pg/mL (range from 98 pg/mL to 492 pg/mL) and mean BNP level was 495 ± 526 pg/mL (range from 52 pg/mL to 2420 pg/mL). At 3 months follow up after percutaneous LAA suture ligation there were no significant differences in ANP and BNP levels.
[Mh] Termos MeSH primário: Apêndice Atrial/cirurgia
Fibrilação Atrial/cirurgia
Fator Natriurético Atrial/sangue
Ligadura/instrumentação
Peptídeo Natriurético Encefálico/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Fibrilação Atrial/sangue
Feminino
Seres Humanos
Masculino
Meia-Idade
Suturas
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
114471-18-0 (Natriuretic Peptide, Brain); 85637-73-6 (Atrial Natriuretic Factor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  5 / 12205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390456
[Au] Autor:Pan Y; Li D; Ma J; Shan L; Wei M
[Ad] Endereço:Department of Cardiology, Shanghai East Hospital.
[Ti] Título:NT-proBNP test with improved accuracy for the diagnosis of chronic heart failure.
[So] Source:Medicine (Baltimore);96(51):e9181, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The circulating concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) has been shown to be a diagnostic tool for the detection of heart failure. Several factors influence NT-proBNP levels including age, sex, and body mass index (BMI). Therefore, the diagnostic sensitivity of NT-proBNP level for heart failure is relatively higher, but its specificity is low. This study aims to improve the diagnostic accuracy rate of this test by including multiple variables in the diagnostic test.The suspected chronic heart failure outpatients were divided into heart failure with reduced ejection fraction, heart failure with mid-range ejection fraction, heart failure with preserved ejection fraction, and normal heart function groups. Area under the receiver-operating characteristic (ROC) curve, cut-off value, and logistic regression analysis were used to select the model variables, sensitivity and specificity.In all, 436 subjects enrolled into this study were divided in 2 groups: model establishment (n = 300) and model validation (n = 136). In the model establishment group, the area under the curve (AUC) and cut-off value of NT-proBNP was 0.926 and 257.4 pg/mL, respectively. When age, glomerular filtration rate, BMI, atrial fibrillation, and sex were entered into the diagnosis model, AUC, sensitivity, and specificity further increased to 0.955 (95% confidence interval [CI] 0.934, 0.976), 94.2% (from 93.0%), and 86.7% (from 74.2%). The ROC curve of corrected NT-proBNP diagnostic formula for heart failure was also significantly higher (P = .037).The corrected NT-proBNP diagnostic formula was found to improve the diagnostic accuracy of chronic heart failure.
[Mh] Termos MeSH primário: Ecocardiografia Doppler/métodos
Insuficiência Cardíaca/sangue
Insuficiência Cardíaca/diagnóstico por imagem
Peptídeo Natriurético Encefálico/sangue
Fragmentos de Peptídeos/sangue
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Área Sob a Curva
Biomarcadores/sangue
China/epidemiologia
Doença Crônica
Bases de Dados Factuais
Testes Diagnósticos de Rotina/métodos
Feminino
Insuficiência Cardíaca/epidemiologia
Seres Humanos
Masculino
Meia-Idade
Curva ROC
Estudos Retrospectivos
Medição de Risco
Sensibilidade e Especificidade
Índice de Gravidade de Doença
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Peptide Fragments); 0 (pro-brain natriuretic peptide (1-76)); 114471-18-0 (Natriuretic Peptide, Brain)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009181


  6 / 12205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29297544
[Au] Autor:Dzudie A; Dzekem BS; Kengne AP
[Ad] Endereço:Department of Medicine, University of Cape Town, Cape Town, South Africa; Douala General Hospital and Clinical Research Education Networking and Consultancy, Douala, Cameroon; Faculty of Health Sciences, University of Buea, Buea, Cameroon. Email: aitdzudie@yahoo.com.
[Ti] Título:NT-pro BNP and plasma-soluble ST2 as promising biomarkers for hypertension, hypertensive heart disease and heart failure in sub-Saharan Africa.
[So] Source:Cardiovasc J Afr;28(6):406-407, 2017 Nov/Dec.
[Is] ISSN:1680-0745
[Cp] País de publicação:South Africa
[La] Idioma:eng
[Mh] Termos MeSH primário: Peptídeo Natriurético Encefálico
Fragmentos de Peptídeos
[Mh] Termos MeSH secundário: África ao Sul do Saara
Biomarcadores
Insuficiência Cardíaca
Seres Humanos
Hipertensão
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Biomarkers); 0 (Peptide Fragments); 114471-18-0 (Natriuretic Peptide, Brain)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE


  7 / 12205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29332917
[Au] Autor:Tsuchida K; Fujihara Y; Hiroki J; Hakamata T; Sakai R; Nishida K; Sudo K; Tanaka K; Hosaka Y; Takahashi K; Oda H
[Ad] Endereço:Department of Cardiology, Niigata City General Hospital.
[Ti] Título:Significance of Sarcopenia Evaluation in Acute Decompensated Heart Failure.
[So] Source:Int Heart J;59(1):143-148, 2018 Jan 27.
[Is] ISSN:1349-3299
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:In patients with chronic heart failure (HF), the clinical importance of sarcopenia has been recognized in relation to disease severity, reduced exercise capacity, and adverse clinical outcome. Nevertheless, its impact on acute decompensated heart failure (ADHF) is still poorly understood. Dual-energy X-ray absorptiometry (DXA) is a technique for quantitatively analyzing muscle mass and the degree of sarcopenia. Fat-free mass index (FFMI) is a noninvasive and easily applicable marker of muscle mass.This was a prospective observational cohort study comprising 38 consecutive patients hospitalized for ADHF. Sarcopenia, derived from DXA, was defined as a skeletal muscle mass index (SMI) two standard deviations below the mean for healthy young subjects. FFMI (kg/m ) was calculated as 7.38 + 0.02908 × urinary creatinine (mg/day) divided by the square of height (m ).Sarcopenia was present in 52.6% of study patients. B-type natriuretic peptide (BNP) levels were significantly higher in ADHF patients with sarcopenia than in those without sarcopenia (1666 versus 429 pg/mL, P < 0.0001). Receiver operator curves were used to compare the predictive accuracy of SMI and FFMI for higher BNP levels. Areas under the curve for SMI and FFMI were 0.743 and 0.717, respectively. Multiple logistic regression analysis showed sarcopenia as a predictor of higher BNP level (OR = 18.4; 95% CI, 1.86-181.27; P = 0.013).Sarcopenia is associated with increased disease severity in ADHF. SMI based on DXA is potentially superior to FFMI in terms of predicting the degree of severity, but FFMI is also associated with ADHF severity.
[Mh] Termos MeSH primário: Insuficiência Cardíaca/complicações
Músculo Esquelético/metabolismo
Sarcopenia/diagnóstico
[Mh] Termos MeSH secundário: Absorciometria de Fóton/métodos
Doença Aguda
Idoso
Biomarcadores/sangue
Biomarcadores/urina
Índice de Massa Corporal
Creatinina/urina
Progressão da Doença
Feminino
Seguimentos
Insuficiência Cardíaca/diagnóstico
Insuficiência Cardíaca/metabolismo
Seres Humanos
Masculino
Músculo Esquelético/diagnóstico por imagem
Peptídeo Natriurético Encefálico/sangue
Estudos Prospectivos
Sarcopenia/etiologia
Sarcopenia/metabolismo
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Biomarkers); 114471-18-0 (Natriuretic Peptide, Brain); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180116
[St] Status:MEDLINE
[do] DOI:10.1536/ihj.17-057


  8 / 12205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Resende, Elmiro Santos
Texto completo
[PMID]:28452559
[Au] Autor:Roever L; Resende ES; Roerver-Borges AS
[Ad] Endereço:1 Federal University of Uberlândia, Department of Clinical Research, Uberlândia, Brazil.
[Ti] Título:Impact of pro-atrial natriuretic peptide in atrial fibrillation and stroke.
[So] Source:Eur J Prev Cardiol;24(12):1239-1241, 2017 08.
[Is] ISSN:2047-4881
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Fibrilação Atrial
Fator Natriurético Atrial
[Mh] Termos MeSH secundário: Biomarcadores
Seres Humanos
Peptídeo Natriurético Encefálico
Fragmentos de Peptídeos
Acidente Vascular Cerebral
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Biomarkers); 0 (Peptide Fragments); 114471-18-0 (Natriuretic Peptide, Brain); 85637-73-6 (Atrial Natriuretic Factor)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1177/2047487317707832


  9 / 12205 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27771699
[Au] Autor:van Breda GF; Bongartz LG; Zhuang W; van Swelm RP; Pertijs J; Braam B; Cramer MJ; Swinkels DW; Doevendans PA; Verhaar MC; Masereeuw R; Joles JA; Gaillard CA
[Ad] Endereço:Department of Nephrology and Immunology, University of Alberta, Edmonton, Alta., Canada.
[Ti] Título:Cardiac Hepcidin Expression Associates with Injury Independent of Iron.
[So] Source:Am J Nephrol;44(5):368-378, 2016.
[Is] ISSN:1421-9670
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hepcidin regulates systemic iron homeostasis by downregulating the iron exporter ferroportin. Circulating hepcidin is mainly derived from the liver but hepcidin is also produced in the heart. We studied the differential and local regulation of hepcidin gene expression in response to myocardial infarction (MI) and/or chronic kidney disease (CKD). We hypothesized that cardiac hepcidin gene expression is induced by and regulated to severity of cardiac injury, either through direct (MI) or remote (CKD) stimuli, as well as through increased local iron content. METHODS: Nine weeks after subtotal nephrectomy (SNX) or sham surgery (CON), rats were subjected to coronary ligation (CL) or sham surgery to realize 4 groups: CON, SNX, CL and SNX + CL. In week 16, the gene expression of hepcidin, iron and damage markers in cardiac and liver tissues was assessed by quantitative polymerase chain reaction and ferritin protein expression was studied by immunohistochemistry. RESULTS: Cardiac hepcidin messenger RNA (mRNA) expression was increased 2-fold in CL (p = 0.03) and 3-fold in SNX (p = 0.01). Cardiac ferritin staining was not different among groups. Cardiac hepcidin mRNA expression correlated with mRNA expression levels of brain natriuretic peptide (ß = 0.734, p < 0.001) and connective tissue growth factor (ß = 0.431, p = 0.02). In contrast, liver hepcidin expression was unaffected by SNX and CL alone, while it had decreased 50% in SNX + CL (p < 0.05). Hepatic ferritin immunostaining was not different among groups. CONCLUSIONS: Our data indicate differences in hepcidin regulation in liver and heart and suggest a role for injury rather than iron as the driving force for cardiac hepcidin expression in renocardiac failure.
[Mh] Termos MeSH primário: Hepcidinas/metabolismo
Ferro/metabolismo
Fígado/metabolismo
Infarto do Miocárdio/metabolismo
Miocárdio/metabolismo
Insuficiência Renal Crônica/metabolismo
[Mh] Termos MeSH secundário: Animais
Proteína Morfogenética Óssea 6/metabolismo
Proteína alfa Estimuladora de Ligação a CCAAT/metabolismo
Proteínas de Transporte de Cátions/metabolismo
Fator de Crescimento do Tecido Conjuntivo/metabolismo
Citocinas/metabolismo
Regulação da Expressão Gênica
Heme Oxigenase (Desciclizante)/metabolismo
Masculino
Peptídeo Natriurético Encefálico/metabolismo
Ratos Endogâmicos Lew
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bmp6 protein, rat); 0 (Bone Morphogenetic Protein 6); 0 (CCAAT-Enhancer-Binding Protein-alpha); 0 (Cation Transport Proteins); 0 (Ctgf protein, rat); 0 (Cytokines); 0 (Hepcidins); 0 (metal transporting protein 1); 114471-18-0 (Natriuretic Peptide, Brain); 139568-91-5 (Connective Tissue Growth Factor); E1UOL152H7 (Iron); EC 1.14.14.18 (Heme Oxygenase (Decyclizing)); EC 1.14.14.18 (Hmox1 protein, rat)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180118
[Lr] Data última revisão:
180118
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  10 / 12205 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29253899
[Au] Autor:Cannone V; Scott CG; Decker PA; Larson NB; Palmas W; Taylor KD; Wang TJ; Gupta DK; Bielinski SJ; Burnett JC
[Ad] Endereço:Cardiorenal Research Laboratory, Mayo Clinic, Rochester, Minnesota, United States of America.
[Ti] Título:A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA).
[So] Source:PLoS One;12(12):e0189858, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In whites, the minor G allele of the atrial natriuretic peptide (ANP) genetic variant rs5068 is associated with higher circulating levels of ANP and B-type natriuretic peptide (BNP), lower risk of hypertension, higher high-density lipoprotein (HDL) cholesterol plasma levels, and lower prevalence of obesity and metabolic syndrome. The observed phenotype is consistent with the blood pressure lowering and metabolic properties of ANP and BNP. The cardiovascular and metabolic phenotype associated with rs5068 genotypes in African Americans is undefined. We genotyped 1631 African Americans in the Multi-Ethnic Study of Atherosclerosis (MESA) for rs5068 and investigated their phenotype. Genotype frequencies of rs5068 were 93.2% AA (n = 1520), 6.7% AG (n = 110) and 0.1% GG (n = 1). All subsequent analyses are AG + GG versus AA genotype. Using a Bonferroni corrected level of significance of 0.005, the prevalence of metabolic syndrome (23% vs 38%, age-sex-adjusted p = 0.002) and triglycerides plasma values (76 vs 90 mg/dl, age-sex-BMI adjusted p = 0.004) were both significantly lower in the AG+GG genotypes. In the AG+GG genotypes, the prevalence of diabetes (8% vs 18%, age-sex-BMI-adjusted p = 0.02) and insulin plasma levels tended to be lower (4.8 vs 5.7 µU/ml, age-sex-BMI adjusted p = 0.04) whereas HDL-cholesterol levels tended to be higher (55 vs 50 mg/dl, age-sex-BMI-adjusted p = 0.04). No association was found with hypertension. The association between the rs5068 G allele and a favorable metabolic phenotype is now shown in African Americans. The rs5068 AG+GG genotypes are associated with lower prevalence of metabolic syndrome and lower triglycerides values.
[Mh] Termos MeSH primário: Aterosclerose/etnologia
Aterosclerose/genética
Fator Natriurético Atrial/genética
Doenças Cardiovasculares/etnologia
Doenças Cardiovasculares/genética
Doenças Cardiovasculares/prevenção & controle
[Mh] Termos MeSH secundário: Afroamericanos
Idoso
Idoso de 80 Anos ou mais
Alelos
Sistema Cardiovascular
HDL-Colesterol/sangue
Estudos de Coortes
Grupos Étnicos
Feminino
Genótipo
Geografia
Seres Humanos
Insulina/sangue
Masculino
Síndrome Metabólica/sangue
Meia-Idade
Peptídeo Natriurético Encefálico/sangue
Obesidade/sangue
Obesidade/genética
Fenótipo
Prevalência
Triglicerídeos/sangue
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Cholesterol, HDL); 0 (Insulin); 0 (Triglycerides); 114471-18-0 (Natriuretic Peptide, Brain); 85637-73-6 (Atrial Natriuretic Factor)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189858



página 1 de 1221 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde